Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-DOTA-Alendronate PET for Breast Calcifications
NCT03542695Phase 1Completed
- Sponsor
- City of Hope
- Start
- Nov 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 64Cu-DOTA-alendronate in breast carcinoma, sponsored by City of Hope. Primary endpoint: Maximum Standardized Uptake Value up to 7 days. Started Nov 2021; status: completed.
02
Drugs
64Cu-DOTA-alendronate
03
Conditions
breast carcinoma
Beyond the preview
Go deeper on NCT03542695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542695.